Belite Bio (NASDAQ:BLTE) Issues Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Belite Bio (NASDAQ:BLTE) posted its quarterly earnings results on Thursday. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.19, FiscalAI reports.

Here are the key takeaways from Belite Bio’s conference call:

• The FDA accepted Belite Bio’s tinlarebant NDA for Stargardt disease with priority review and a February 12, 2027 PDUFA date; the agency will not hold an advisory committee meeting. The company has also filed in Japan and through the U.K., Switzerland, and Singapore’s Access Consortium.
• Belite reported $774 million in cash, cash equivalents, and U.S. Treasury bills and said its cash runway should support a potential tinlarebant launch and continued pipeline development. Management cautioned that commercialization remains subject to regulatory approval.
• The company is preparing for a potential launch, including building a Japan team and engaging payers and pharmacy benefit managers. Management cited about 10,000 Stargardt patients in Japan and said it expects rare-disease pricing, but did not provide a specific price or label expectation.
• Quarterly expenses and losses increased year over year: GAAP R&D rose to $15.5 million, SG&A to $21.4 million, and net loss to $30.3 million. Belite also said its GA interim analysis is not yet finalized and will be pursued after the February PDUFA, prioritizing the Stargardt review in the meantime.

Belite Bio Stock Up 9.0%

Shares of BLTE opened at $169.96 on Friday. Belite Bio has a 12-month low of $105.88 and a 12-month high of $200.00. The firm has a market capitalization of $6.84 billion, a PE ratio of -62.26 and a beta of -1.19. The stock’s fifty day simple moving average is $161.02 and its 200-day simple moving average is $160.25.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BLTE. Jefferies Financial Group reiterated a “hold” rating on shares of Belite Bio in a research note on Wednesday, September 9th. Mizuho boosted their price target on Belite Bio from $220.00 to $234.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research note on Friday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $245.00 price target on shares of Belite Bio in a research report on Thursday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a research report on Friday, October 2nd. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $227.40.

Key Belite Bio News

Here’s some of the latest news about BLTE:

• Positive Sentiment: The FDA accepted Belite Bio’s new drug application for tinlarebant and granted priority review, advancing the company’s potential treatment for Stargardt disease toward a regulatory decision. This is an important milestone for the clinical-stage biotech; the earnings coverage cites an expected FDA decision timeline. Belite Bio Q3 2026 Earnings Call Highlights Belite Bio Q3 2026: FDA Clock Ticks Toward a First-Ever Stargardt Treatment
• Positive Sentiment: BLTE reported a quarterly loss of $0.60 per share, narrower than the $0.79 loss analysts expected. The shares also moved above their 200-day moving average, a potentially supportive technical signal. Belite Bio earnings results Share Price Breaks Above Two Hundred Day Moving Average
• Negative Sentiment: Belite Bio reported a $30.3 million net loss for the quarter, highlighting continued costs and cash-burn risk as it advances its drug programs. Belite Bio Q3 2026 Financial Results and Corporate Update Belite Bio reveals quarterly loss

Insider Activity

In other Belite Bio news, CEO Yu-Hsin Lin sold 74,435 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $187.71, for a total value of $13,972,193.85. Following the transaction, the chief executive officer directly owned 96,134 shares of the company’s stock, valued at approximately $18,045,313.14. This trade represents a 43.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Hao-Yuan Chuang sold 49,433 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $187.64, for a total transaction of $9,275,608.12. Following the completion of the transaction, the chief financial officer directly owned 44,000 shares in the company, valued at approximately $8,256,160. The trade was a 52.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 168,330 shares of company stock valued at $31,969,118. 13.29% of the stock is currently owned by insiders.

Belite Bio Company Profile

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.